Method and a pharmaceutical composition for the inhibition of angiogenesis
AssigneesChildren's Medical Center Corporation, Takeda Chemical Industries, Ltd.
InventorsJudah Folkman, Takeshi Fujita, Donald Ingber, Tsuneo Kanamaru
Life of this patent
Estimating the term…
Abstract
Fumagillin and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization. The invention also provides certain pharmaceutical compositions comprising fumagillin or its salt, and an agent which potentiates angiogenesis inhibition such as heparin and sulfated cyclodextrins such as beta-cyclodextrin tetradecasulfate.
Claims13
A method of inhibiting angiogenesis in a mammal, comprising administering an amount of fumagillin effective for the inhibition of angiogenesis or a pharmaceutically acceptable salt thereof to the mammal.
A method of preventing angiogenesis in a mammal, comprising administering an amount of fumagillin effective for the prevention of angiogenesis or a pharmaceutically acceptable salt thereof to the mammal.
A pharmaceutical composition for the treatment of angiogenesis in mammals comprising fumagillin or a pharmaceutically acceptable salt thereof and a potentiator of said fumagillin selected from heparin and a sulfated cyclodextrin, the ratio o potentiator to fumagillin by weight being between about 1:10 to 30:1.
Dependencies are inferred from the claim text.